Stocks and Investing Stocks and Investing
Fri, July 28, 2023

Christopher Raymond Maintained (ABBV) at Buy with Increased Target to $170 on, Jul 28th, 2023


Published on 2024-10-28 05:13:20 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $163 to $170 on, Jul 28th, 2023.

Christopher has made no other calls on ABBV in the last 4 months.



There are 7 other peers that have a rating on ABBV. Out of the 7 peers that are also analyzing ABBV, 3 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tim Lugo of "William Blair" Initiated at Hold on, Tuesday, July 25th, 2023
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $160 on, Thursday, April 13th, 2023
  • Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Wednesday, April 5th, 2023


These are the ratings of the 4 analyists that currently disagree with Christopher


  • Rajesh Kumar of "HSBC" Initiated at Strong Buy and Held Target at $167 on, Friday, July 14th, 2023
  • Terence Flynn of "Morgan Stanley" Reiterated at Buy and Held Target at $182 on, Tuesday, July 11th, 2023
  • Vamil Divan of "Guggenheim" Maintained at Strong Buy with Decreased Target to $171 on, Friday, April 28th, 2023
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Decreased Target to $195 on, Friday, April 28th, 2023
Contributing Sources